Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | TSHR | P16473 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxolinic Acid SCHEMBL7219626 | 0.89 | ALDH1A1 (0.74) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Piromidic Acid SCHEMBL7164756 | 0.82 | LMNA (0.66) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Cinoxacin SCHEMBL28034323 | 0.82 | KDM4E (0.97) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Rosoxacin SCHEMBL13725083 | 0.82 | KDM4E (0.64) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Cinoxacin SCHEMBL43770 | 0.81 | KDM4E (1.00) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Cinoxacin SCHEMBL29471771 | 0.81 | KDM4E (1.00) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Oxolinic Acid SCHEMBL7855172 | 0.81 | KDM4E (0.68) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Cinoxacin SCHEMBL28034322 | 0.80 | KDM4E (0.97) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Nalidixic Acid SCHEMBL7878858 | 0.78 | KMT2A (1.00) | ALDH1A1TSHRLMNAKDM4EBLM | |
| Nalidixic Acid SCHEMBL21736 | 0.78 | KMT2A (1.00) | ALDH1A1TSHRLMNAKDM4EBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545613-A4 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1912671-A2 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1817336-A2 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | Seattle Genetics, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007011968-A2 | BETA-GLUCURONIDE-LINKER DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006132670-A2 | AURISTATINS HAVING AN AMINOBENZOIC ACID UNIT AT THE N TERMINUS | SEATTLE GENETICS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1545613-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | Seattle Genetics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003026577-A2 | P-AMIDOBENZYLETHERS IN DRUG DELIVERY AGENTS | SEATTLE GENETICS, INC. (US) | 2003-04-03 | — | — | WO | disclosed |